Fortress Biotech (FBIO) 10-Q 10 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 07, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		46,833,715

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 41,037	$ 49,759
Marketable securities, at fair value (Note 3)	20,000	20,002
Prepaid expenses and other current assets	997	702
Total current assets	62,034	70,463
Property and equipment, net	90	52
Restricted cash	14,586	14,586
Long-term investments, at fair value (Note 11)	5,567	4,160
Intangible asset - license (Note 6)	1,250	0
Other assets	172	64
Total assets	83,699	89,325
Current liabilities
Accounts payable	583	366
Interest payable	26	28
Accrued expenses	4,386	3,683
Total current liabilities	4,995	4,077
Notes payable, long-term, net (net of debt discount of $777 and $6 at June 30, 2015 and December 31, 2014, respectively)	23,232	14,003
Other long-term liabilities	264	722
Total liabilities	$ 28,491	$ 18,802
Commitments and contingencies
Stockholders' equity
Common Stock, $.001 par value, 100,000,000 shares authorized, 46,833,715 and 46,494,034 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	$ 47	$ 46
Additional paid-in capital	215,793	212,205
Accumulated deficit	(159,959)	(141,728)
Total stockholders' equity attributed to the Company	55,881	70,523
Non-controlling interest (Note 5)	(673)	0
Total stockholders' equity	55,208	70,523
Total liabilities and stockholders' equity	83,699	89,325
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Convertible Preferred stock, $.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument, Unamortized Discount	$ 777	$ 6
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	46,833,715	46,494,034
Common Stock, shares outstanding	46,833,715	46,494,034
Series C Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	129,767	129,767
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue	$ 0	$ 0	$ 500	$ 0
Operating expenses
Research and development	2,411	2,377	4,066	6,865
Research and development - licenses acquired	1,548	0	8,987	0
General and administrative	3,803	2,386	7,280	4,481
Total operating expenses	7,762	4,763	20,333	11,346
Loss from operations	(7,762)	(4,763)	(19,833)	(11,346)
Other income (expenses)
Interest income	74	171	156	350
Interest expenses	(352)	(119)	(683)	(1,085)
Change in fair value of investments	1,622	0	1,407	0
Total other income (expenses)	1,344	52	880	(735)
Net loss	(6,418)	(4,711)	(18,953)	(12,081)
Less: net loss attributable to non-controlling interest	243	0	722	0
Net loss attributable to common stockholders	$ (6,175)	$ (4,711)	$ (18,231)	$ (12,081)
Basic and diluted net loss per common share	$ (0.16)	$ (0.13)	$ (0.47)	$ (0.34)
Weighted average common shares outstanding-basic and diluted	39,119,606	36,005,294	38,848,660	35,953,234

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows from Operating Activities:
Net Loss	$ (18,953)	$ (12,081)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	11	11
Noncash interest expense	167	555
Amortization of debt discount	84	0
Stock-based compensation expenses - Fortress	3,395	2,598
Change in fair value of investment	(1,407)	0
Asset impairment loss	0	723
Unrealized gain on marketable securities	2	0
Increase (decrease) in cash resulting from changes in assets and liabilities:
Prepaid expenses and other current assets	(295)	124
Accounts payable and accrued expenses	920	(1,486)
Interest payable	(2)	(84)
End of term fee associated with Hercules Note	0	(398)
Other long term liabilities	(624)	(50)
Net Cash used in Operating Activities	(16,702)	(10,088)
Cash Flows from Investing Activities:
Purchase of short- term investment	0	(295)
Purchase of long-term investment	0	(250)
Purchase of property and equipment	(49)	0
Purchase of license	(1,250)	0
Payment to related parties - CB Pharma Acquisition Corp	(108)	0
Net Cash used in Investing Activities	(1,407)	(545)
Cash Flows from Financing Activities:
Payment of Hercules Note	0	(13,655)
Proceeds from issuance of common stock	0	606
Proceeds from the exercise of stock options	216	0
Proceeds from issuance of common stock under ESPP	26	0
Payment of costs related to the issuance of Common Stock	0	(32)
Proceeds from IDB note	0	14,009
Payment of debt issue costs associated with IDB Note	0	(9)
Proceeds from NSC note	10,000	0
Payment of debt issue costs associated with NSC Note	(855)	0
Transfer of restricted cash	0	(14,009)
Net Cash provided by (used in) Financing Activities	9,387	(13,090)
Net decrease in cash and cash equivalents	(8,722)	(23,723)
Cash and cash equivalents at beginning of period	49,759	99,521
Cash and cash equivalent at end of period	41,037	75,798
Supplemental disclosure of cash flow information:
Cash paid for interest	80	614
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	$ 1	$ 4

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Fortress Biotech, Inc., formerly Coronado Biosciences, Inc. (“Fortress” or “the Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. On April 27, 2015, the Company changed its name from Coronado Biosciences, Inc. to Fortress Biotech, Inc. Fortress plans to develop and commercialize products both within Fortress and within subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, the Company will leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals. Additionally, the Company will provide funding and management services to each of the Fortress Companies and, from time to time, the Company and the Fortress Companies will seek licensing, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. As of June 30, 2015, the Company has several consolidated Fortress Companies, which contain product licenses, Journey Medical Corporation (“JMC”), Coronado SO Co. (“Coronado SO”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Mustang Bio, Inc. (“Mustang”), Helocyte Inc. (“Helocyte”) formerly Helocyte Biosciences (“Helocyte”), and other consolidated Fortress subsidiaries, which have minimal activity: Avenue Therapeutics, Inc. (“Avenue”), Innmune Limited, CB Securities Corporation (holds treasury bills classified as marketable securities), Cyprium Inc., and Altamira Bio Inc. Fortress Epidermal Growth Factor Receptors (“EGFR”) Inhibitors In March 2015, the Company entered into an exclusive license agreement with NeuPharma, Inc. (“NeuPharma”) to develop and commercialize novel irreversible, 3rd Generation EGFR inhibitors on a worldwide basis other than certain Asian countries. The program is currently in pre-clinical development ( see Note 4). Fortress Companies Checkpoint Therapeutics, Inc. In March 2015, the Company formed Checkpoint, a Fortress Company, Checkpoint, to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDS at the Dana-Farber Cancer Institute (“Dana-Farber”). The portfolio includes antibodies targeting Programmed-death Ligand 1 (“PD-L1”), glucocorticoid-induced TNFR-related protein (“GITR”) and carbonic anhydrase 9 (“CAIX”). Checkpoint plans to develop these novel immuno-oncology and checkpoint inhibitor antibodies on their own and in combination with each other, as data suggests that combinations of these targets can work synergistically together. The Company expects clinical trials to start in the second half of 2016 (see Note 4). In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TG Therapeutics, Inc. (“TGTX”) to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. Michael Weiss, the Company’s Executive Vice Chairman, Strategic Development is also Co-Portfolio Manager and a Partner of Opus Point Partners Management, LLC (“OPPM”) with Dr. Rosenwald, the Company’s Chairman and Chief Executive Officer. Further, Michael Weiss is the Executive Chairman, Interim President and Chief Executive Officer and a stockholder of TGTX. Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Both programs are currently in pre-clinical development. Mustang Bio, Inc. In March 2015, the Company formed Mustang to develop immunotherapies based on Chimeric Antigen Receptor Technology (“CAR-T”) and Mustang entered into a license agreement with the City of Hope (“COH”) to acquire such technology. In connection with the license agreement, Mustang also entered into a Sponsored Research Agreement with the COH in which Mustang will fund continued research at COH of CAR-T (see Note 4). Coronado SO Company In February 2015, Coronado SO entered into an exclusive license agreement with a third party for a topical product used in the treatment of Hand-Foot Syndrome, a common painful side effect of chemotherapeutics (see Note 4). Journey Medical Corporation In March 2015, JMC, the Company’s dermatology focused subsidiary, entered into a license and supply agreement to acquire rights to distribute a dermatological product for the treatment of acne (see Note 6). Avenue Therapeutics, Inc. In February 2015, the Company purchased an exclusive license to an intravenous (“IV”) formulation of Tramadol for the U.S. market from Revogenex Ireland Ltd (“Revogenex”). Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain and is available as immediate release or extended-release tablets in the U.S. The Company intends to transfer the IV Tramadol license and rights to Avenue during the second half of 2015 in order to establish a Fortress Company focused on the acquisition, license, development and commercialization of products principally for use in the acute/intensive care hospital setting (see Note 4). Helocyte Biosciences, Inc. On July 1, 2015, DiaVax Biosciences, Inc., which was formed in March 2015, filed a Certificate of Amendment with the State of Delaware, changing its name to Helocyte Biosciences, Inc. (“Helocyte”). Helocyte was formed to develop novel immunotherapies for the prevention and treatment of cytomegalovirus (“CMV”), a common virus that affects people of all ages. On April 2, 2015, Helocyte, entered into an agreement with the City of Hope (“COH”) to secure exclusive worldwide rights (the “License”), for two T-cell immunotherapeutic vaccines for controlling CMV in allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. Known as Triplex and PepVax, the programs are expected to enter Phase II clinical studies later this year and are supported by grants paid and payable to COH from the National Cancer Institute. In connection with the licensing of Triplex and PepVax, Helocyte further entered into an option agreement with COH (the “Option”) for exclusive worldwide rights to Pentamer, a universal immunotherapeutic vaccine being developed for the prevention of CMV transmission in utero and exercised this option on April 28, 2015 (see Note 4).

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission, or SEC, on March 16, 2015, from which the Company derived the balance sheet data at December 31, 2014. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Innmune Limited, Coronado SO, Cyprium Inc., Altamira Bio Inc., JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang and Helocyte. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. The Company reclassified debt issuance costs from other assets to notes payable, long-term, net on the unaudited condensed consolidated balance sheets for all periods presented pursuant to the early adoption of Accounting Standards Update ("ASU") No. 2015-03 - Simplifying the Presentation of Debt Issuance Costs The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of June 30, 2015, the Company has $ 14.6 14.0 0.6 The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 : Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed upon the acquisition of certain manufacturing rights in December 2012 under the amendment to the sublicense agreement with Ovamed included in current liabilities in the June 30, 2015 Unaudited Condensed Consolidated Balance Sheet and both current liabilities and long-term liabilities in the December 31, 2014 Consolidated Balance Sheet, has been recorded at its net present value, which approximates its fair value (see Note 11). The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. During the three and six month period ended June 30, 2014, in relation to the abandonment of its lease in Woburn, MA, the Company recorded an impairment loss of $ 0.4 The Company elected the fair value option for its investment in a third-party company developing a laser device to treat migraine headaches, and its investment in CB Pharma Acquisitions Corp (“CB Pharma”). As of June 30, 2015 the fair value of these investments approximate $ 5.6 While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected, are recognized as a change in fair value of investments, in the Unaudited Condensed Consolidated Statements of Operations. The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. The Company follows ASC 605-25, Revenue Recognition Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the Unaudited Condensed Consolidated Balance Sheets and recognized as revenue in the Unaudited Condensed Consolidated Statements of Operations when the related revenue recognition criteria are met. The Company records the costs of acquired product license rights as intangible asset licenses in the Condensed Consolidated Balance Sheets. Upon commencement of product sales, license rights will be amortized over the expected life of the product into product expense in the Unaudited Condensed Consolidated Statements of Operations. As of June 30, 2015, product sales of the Company’s intangible asset license had not yet commenced (see Note 6). The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50 Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests (see Note 5). The Company’s comprehensive loss is equal to its net loss for all periods presented. In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs In the first quarter of 2015, the Company adopted ASU No. 2014-08, Reporting Discontinued operations and Disclosures of Disposals of Components of an Entity In January 2015, the FASB issued ASU 2015-01, which eliminates from GAAP the concept of extraordinary items. If an event or transaction meets the criteria for extraordinary classification, it is segregated from the results of ordinary operations and is shown as a separate item in the income statement, net of tax. ASU 2015-01 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company is currently assessing the adoption and impact of this ASU, however, the Company does not anticipate that adoption of this ASU will impact consolidated financial position and results of operations In May 2014, the FASB issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2015
Investments, Debt and Equity Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure	3. Marketable Securities As of June 30, 2015 ($ in thousands) Cost Unrealized Gain/(Loss) Fair Value U.S. treasury bill $ 19,998 $ 2 $ 20,000 As of December 31, 2014 ($ in thousands) Cost Unrealized Gain/(Loss) Fair Value U.S. treasury bill $ 19,998 $ - $ 19,998 Mutual fund 4 - 4 $ 20,002 $ - $ 20,002 The contractual term to maturity of all marketable securities held by the Company as of June 30, 2015 is less than one year.

Licenses Acquired

Licenses Acquired	6 Months Ended
	Jun. 30, 2015
Licenses Acquired [Abstract]
Licenses Acquired	4. Licenses Acquired In accordance with ASC 730-10-25-1, Research and Development 9.0 For the Six Months ($ in thousands) Ended June 30, 2015 Fortress: EGFR inhibitors $ 1,000 IV Tramadol (1) 3,000 Fortress Companies: Mustang 2,147 Checkpoint 1,033 Coronado SO 1,607 Helocyte 200 Total $ 8,987 (1) The Company intends to transfer this license to Avenue. Research and Development Licenses Acquired Fortress Epidermal Growth Factor Receptors (“EGFR”) Inhibitors In March 2015, the Company entered into an exclusive license agreement with NeuPharma to develop and commercialize novel irreversible, 3rd Generation EGFR inhibitors on a worldwide basis other than certain Asian countries. Under the terms of the agreement, the Company paid NeuPharma an up-front licensing fee of $ 1.0 Fortress Companies Checkpoint Therapeutics, Inc. License Agreement with Dana-Farber Cancer Institute In March 2015 Checkpoint entered into a license agreement with Dana-Farber to develop a portfolio of fully human immuno-oncology targeted antibodies. Under the terms of the agreement, Checkpoint paid Dana-Farber an up-front licensing fee of $ 1.0 500,000 Dr. Wayne Marasco, MD, PhD, a professor in the Department of Cancer Immunology and AIDS at Dana-Farber whose laboratory generated the immune-oncology targeted antibodies, will chair the Scientific Advisory Board of Checkpoint. As payment for these services Checkpoint granted Dr.Marasco 1,500,000 0.2 An independent consultant valued the restricted stock Checkpoint granted to Dr. Marasco utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 0.065 0.1 25 48 During the three and six months ended June 30, 2015, Checkpoint recorded expense of approximately $ 9,000 12,000 The 500,000 44.8 30 0.065 32,500 Collaboration Agreement with TG Therapeutics In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. Under the terms of the agreements, Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Both programs are currently in pre-clinical development. TGTX paid Checkpoint $ 0.5 0 0.5 Mustang Bio, Inc. License Agreement with the City of Hope In March 2015, Mustang entered into a license agreement with the City of Hope (“COH”) to acquire CAR-T technology. Pursuant to the agreement, in April 2015, Mustang paid the COH an upfront fee of $ 2.0 1,000,000 2.0 An independent consultant valued the stock grant to the COH utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 0.147 0.1 0.1 Coronado SO Company License Agreement In February 2015, Coronado SO entered into an exclusive license agreement with a third party for a topical product used in the treatment of Hand-Foot Syndrome, a common painful side effect of chemotherapeutics. Coronado SO paid $ 0.9 150,000 0.5 1.4 An independent consultant valued the stock grant to the third party utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 1.19 0.2 Avenue Therapeutics, Inc. License Agreement with Revogenex Ireland Ltd In February 2015, the Company purchased an exclusive license to an intravenous (“IV”) formulation of Tramadol for the U.S. market from Revogenex Ireland Ltd (“Revogenex”), a privately held company in Dublin, Ireland. Fortress made an upfront payment of $ 2.0 1.0 The Company intends to transfer the IV Tramadol license and rights to Avenue during the second half of 2015 in order to establish a Fortress Company focused on the acquisition, license, development and commercialization of products principally for use in the acute/intensive care hospital setting. During the three month ended June 30, 2015, Avenue granted 150,000 1,000,000 grant vests 50% in four annual equal tranches of 12.5%, with the remaining 50% vesting upon the achievement of certain performance goals. 23,000 An independent consultant valued the stock utilizing a discounted cash flow model to determine the weighted market value of invested capital, discounted by a lack of marketability of 44.8 30 0.146 Helocyte Biosciences, Inc. License Agreement with COH On April 2, 2015, Helocyte, entered into an agreement with COH to secure the exclusive license to the worldwide rights, for two T-cell immunotherapeutic vaccines for controlling CMV in allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients, for an upfront payment of $ 150,000 500,000 50,000 0.2

Non-Controlling Interests

Non-Controlling Interests	6 Months Ended
	Jun. 30, 2015
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure	5. Non-Controlling Interests ($ in thousands) As of June 30, 2015 Avenue Coronado SO Mustang Checkpoint Total NCI equity share 2 23 15 9 49 Net loss attributed to non-controlling interest (34) (230) (267) (191) (722) Non-controlling in consolidated entities $ (32) $ (207) $ (252) $ (182) $ (673) ($ in thousands) For the six months ended June 30, 2015 Avenue Coronado SO Mustang Checkpoint Total Non-controlling interests in loss of consolidated entities $ (34) $ (230) $ (267) $ (191) $ (722) Non-controlling ownership (See Note 4) 11.5 % 13.0 % 10.0 % 20.0 %

Intangible Asset License

Intangible Asset License	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure	6. Intangible Asset License Journey Medical Corporation In March 2015, Journey Medical Corporation (“JMC”) entered into a license and supply agreement to acquire the rights to distribute a dermatological product for the treatment of acne. JMC made an upfront payment of $ 1.3 0.7 The Company recorded the upfront payment as an intangible asset on the Unaudited Condensed Consolidated Balance Sheets as of June 30, 2015 and will amortize it over the deemed life of the product or agreement; whichever is shorter, upon the commencement of sales, which the Company expects will commence in late 2015 or early 2016. The product is fully developed and approved but sales cannot commence until manufacturing regulatory clearance is obtained.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Common Share	7. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period. For the three months ended June 30, For the six months ended June 30, ($ in thousands except share and per share amounts) 2015 2014 2015 2014 Net loss (6,175) (4,711) (18,231) (12,081) Weighted average common shares outstanding—basic and diluted 39,119,606 36,005,294 38,848,660 35,953,234 Basic and diluted net loss per common share $ (0.16) $ (0.13) $ (0.47) $ (0.34) Included in common stock issued and outstanding as of June 30, 2015 are 7,704,269 The Company’s potential dilutive securities which consist of unvested restricted stock, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same. For the three months ended June 30, For the six months ended June 30, 2015 2014 2015 2014 Warrants to purchase Common Stock 685,061 692,916 685,061 702,353 Options to purchase Common Stock 2,071,032 2,187,076 2,114,126 2,384,348 Unvested Restricted Stock 6,912,530 6,308,368 6,749,641 5,662,528 Unvested Restricted Stock Units 11,000 - 6,884 - Total 9,679,623 9,188,360 9,555,712 8,749,229

Debt and Interest

Debt and Interest	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt	8. Debt and Interest Debt ($ in Thousands) June 30, 2015 December 31, 2014 Interest Rate Maturity IDB Note $ 14,009 $ 14,009 2.25 % Feb - 2017 NSC Note 10,000 - 8.00 % Mar - 2018 Total notes payable, long term 24,009 14,009 Discount of notes payable 777 - Total notes payable, long term, net $ 23,232 $ 14,009 Israel Discount Bank Note (“IDB Note”) At June 30, 2015, the Company had $ 14.0 NSC Note In March 2015, the Company closed a private placement of a promissory note for $ 10 8 0.9 9 The NSC Note, was amended and restated on July 29, 2015, to provide that any time a Fortress Company receives from the Company any proceeds from the NSC Note, the Company may, in its sole discretion, cause the Fortress Company to issue to NSC Biotech Venture Fund I LLC a new promissory note (the “Amended NSC Note”) on identical terms as the NSC Note (giving effect to the passage of time with respect to maturity). The Amended NSC Note will equal the dollar amount of the Fortress Company’s share of the NSC Note and reduce the Company’s obligations under the NSC Note by such amount. The Company will guarantee the Amended NSC Note until the Fortress Company either completes an initial public offering of its securities or raises sufficient equity capital so that it has cash equal to five times the Amended NSC Note. In connection with the transfer of NSC Note proceeds to a Fortress Company, NSC will receive a warrant to purchase the Fortress Company’s stock equal to 25 10 Interest The following table shows the details of interest expense for all of debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: For the three months ended June 30, For the six months ended June 30, ($ in Thousands) 2015 2014 2015 2014 IDB Note Interest $ 82 $ 80 $ 153 $ 121 Amortization of fees 1 1 2 2 Total IDB Note 83 81 155 123 NSC Debt Interest 208 - 279 - Amortization of fees 61 - 82 - Total NSC Debt 269 - 361 - Ovamed Manufacturing Agreement Interest - 38 167 75 Total Ovamed - 38 167 75 Hercules Debt Interest (1) - - - 845 Amortization of fees - - - 42 Total Hercules Debt - - - 887 Total Interest Expense $ 352 $ 119 $ 683 $ 1,085 (1) Interest expense related to the Hercules Note was $ 0.8 0.4

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property Plant And Equipment [Abstract]
Property and Equipment	9. Property and Equipment ($ in thousands) Useful Life (Years) As of June 30, 2015 As of December 31, 2014 Computer equipment 3 $ 13 $ 13 Furniture & fixtures 5 69 69 Leasehold improvements 5 12 12 Construction in progress N/A 49 - Total property and equipment 143 94 Less: Accumulated depreciation (53) (42) Property and equipment, net $ 90 $ 52 Depreciation expense for the three months ended June 30, 2015 and 2014 was $ 5,000 6,000 11,000 11,000

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	10. Accrued Expenses and Other Long-Term Liabilities In December 2012, the Company acquired certain manufacturing rights from Ovamed GmbH (“Ovamed”) and agreed to pay an aggregate of $ 1.5 0.5 1.5 38,000 167,000 75,000 June 30, 2015 December 31, 2014 Accrued expenses: Professional fees $ 359 $ 837 Salaries, bonuses and related benefits 640 598 Accrued milestone, CNDO SO 500 - Accrued severance 6 38 Ovamed manufacturing rights - short term component 1,500 1,000 Research and development 623 832 Lease impairment 165 165 Other 593 213 Total accrued expenses $ 4,386 $ 3,683 Other long-term liabilities: Ovamed manufacturing rights – long-term component - 334 Long-term lease abandonment charge 144 268 Deferred rent 120 120 Total other long-term liabilities $ 264 $ 722

Investments at Fair Value

Investments at Fair Value	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurement	11. Investments at Fair Value From time to time, the Company invests in marketable securities, which are classified as trading securities and are stated at fair value as determined by quoted market prices. As of both June 30, 2015 and December 31, 2014, the Company held approximately $ 20.0 The fair value of the Company’s investment of $ 250,000 As of June 30, 2015, the Company valued its investment in CB Pharma, a publicly traded company, utilizing the following assumptions: volatility of 25.4 9.52 9.52 25.4 1.63 11.50 0.86 0.87 1.4 5.3 42.9 0.5 0.1 Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. Fair Value Measurement as of June 30, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Marketable securities: U.S. treasury bills $ 20,000 $ - $ - $ 20,000 Total marketable securities 20,000 - - 20,000 Long-term investments, at fair value - - 5,567 5,567 Total $ 20,000 $ - $ 5,567 $ 25,567 Fair Value Measurement as of December 31, 2014 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Marketable securities: U.S. treasury bills $ 19,998 $ - $ - $ 19,998 Mutual funds 4 - 4 Total marketable securities 20,002 - - 20,002 Long-term investments, at fair value - - 4,160 4,160 Total $ 20,002 $ - $ 4,160 $ 24,162 The fair value of marketable securities are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date. ($ in thousands) Other CB Pharma Total Balance at December 31, 2014 $ 250 $ 3,910 $ 4,160 Purchases - - - Change in fair value of investment - 1,407 1,407 Balance at June 30, 2015 $ 250 $ 5,317 $ 5,567 For the three and six months ended June 30, 2015, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Shareholders' Equity and Share-based Payments	12. Stockholders’ Equity Stock-based Compensation As of June 30, 2015, the Company had three equity compensation plans: the Fortress Biotech, Inc. 2007 Stock Incentive Plan, the Fortress Biotech, Inc. 2013 Stock Incentive Plan, and the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan. For the three months ended June 30, For the six months ended June 30, ($ in thousands) 2015 2014 2015 2014 Employee awards $ 1,525 $ 1,452 $ 2,988 $ 2,574 Non-employee awards 7 11 14 24 Fortress Companies (1) 35 - 393 - Total stock-based compensation expense $ 1,574 $ 1,463 $ 3,395 $ 2,598 (1) Includes for Avenue $ 22,900 178,500 32,500 12,242 147,000 For the three months ended June 30, 2015 and 2014, $ 0.3 1.3 0.3 1.2 For the six months ended June 30, 2015 and 2014, $ 0.5 2.5 0.6 2.0 Weighted average Total weighted remaining Weighted average average intrinsic contractual life ($ in thousands) Number of shares exercise price value (years) Options vested and expected to vest at December 31, 2014 2,164,365 $ 4.69 $ - 7.38 Options granted - - - Options exercised (100,000) 2.15 1.21 Options cancelled - - - Options vested and expected to vest at June 30, 2015 2,064,365 $ 4.82 $ - 7.20 Options vested and exercisable 1,747,698 $ 4.75 $ - 6.79 Weighted average grant date fair Number of shares value Unvested balance at December 31, 2014 8,287,384 $ 2.33 Restricted stock granted 200,000 3.04 Restricted stock vested (783,115) 2.43 Restricted stock units granted 61,000 2.34 Restricted stock units vested (25,000) 2.19 Unvested balance at June 30, 2015 7,740,269 $ 2.34 As of June 30, 2015, the Company had unrecognized stock-based compensation expense related to unvested stock options and restricted stock awards and restricted stock units of $ 0.7 14.3 0.4 2.5 Warrants As of June 30, 2015 and December 31, 2014 the Company had vested warrants to purchase 685,061 6.65 Deferred Compensation Plan On March 12, 2015, the Company’s Compensation Committee approved the Deferred Compensation Plan allowing all non-employee directors the opportunity to defer all or a portion of their fees or compensation, including restricted stock and restricted stock units. During the six months ended June 30, 2015, certain non-employee directors elected to defer 250,000 Employee Stock Purchase Plan As of June 30, 2015, 77,875 122,125 8,465 7,128 14,848 15,746 Fortress Companies Checkpoint In March 2015, Checkpoint issued a restricted stock grant to Dr. Wayne Marasco for services in connection with their scientific advisory board. Dr. Marasco was issued a grant for 1.5 25 48 44.8 30 0.065 Avenue During the three months ended June 30, 2015, Avenue granted 150,000 1.0 44.8 0.146 50 12.5 50 23,000

Related Party Note

Related Party Note	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Note	13. Related Party Note Related Party Service Agreement On April 3, 2014, the Company entered into a Shared Services Agreement with OPPM in which the parties agreed to share a rented facility as well as costs for certain services, which they individually require for the operation of their respective entities. The Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development, are both Co-Portfolio Managers and Partners of OPPM. The Company incurred expense of approximately $ 44,400 87,700 38,400 Checkpoint Collaboration Agreement with TGTX In connection with the license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. In connection with this Agreement TGTX paid an upfront fee of $ 0.5 CB Pharma Acquisition Corp. The receivable from CB Pharma Acquisition Corp at June 30, 2015 and December 31, 2014 was $0.1 million and nil, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Altamira Bio, Inc . On July 16, 2015, Fortress completed the transaction in which its Fortress Company, Altamira Bio, acquired from New Zealand Pharmaceuticals Ltd (NZP), a license from the National Institutes of Health (NIH) and Cooperative Research and Development Agreements (CRADAs) for the development of oral N-acetyl-D-mannosamine (ManNAc), a key compound in the sialic biosynthetic pathway, for the treatment of hyposialylation disorders, including GNE myopathy and various forms of nephropathy. As part of this agreement, Altamira provided NZP and NIH an upfront payment of approximately $ 1.3 0.7 0.6 Scientific Collaboration Agreement In July 2015, Fortress entered into a collaboration agreement with a leader in yeast based, fully human antibody discovery and optimization using a proprietary core technology platform. Under the terms of the agreement Fortress collaborate with this leader with at least four and potentially six projects. Fortress will paid an upfront fee of $ 50,000 George Avgerinos Grant On July 15, 2015, Mr. George Avgerinos, Senior Vice President of Fortress was granted 1.0 200,000 The restricted shares vest 10% immediately and an additional 10% per year over four years commencing the later of trading availability, under Fortress’ Insider Trading Policy, or July 15, 2015. The remaining 50% vests in accordance with the achievement of performance goals. David Barrett On July 15, 2015, the Board of Directors voted to accelerate the vesting of 133,000 Dov Klein On July 15, 2015, Mr. Dov Klein joined the Board of Directors of Fortress. In connection with Mr. Klein joining the Board he was granted 50,000 25 four years Long-Term Incentive Program At the Company’s stockholders Meeting on July 15, 2015 the shareholders’ also approved the Fortress Biotech, Inc. Long Term Incentive Plan (the “LTIP”) for the Company’s Chairman, President and Chief Executive Officer, Lindsay A. Rosenwald, M.D., and Executive Vice Chairman, Strategic Development, Michael S. Weiss. The LTIP consists of a program to grant equity interests in the Company and newly formed subsidiaries and a performance- based bonus program that is designed to result in performance-based compensation that is deductible without limit under Section 162(m) of the Internal Revenue Code of 1986, as amended. Dr. Falk Pharma GmbH (“Falk”) On August 3, 2015, the Company received notification from Falk that the Final Clinical Study Report, or CSR has been completed and that Falk is prepared to grant access to the CSR. Upon receipt of access to the CSR, the Company will record the liability of € 2.5 2.7

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission, or SEC, on March 16, 2015, from which the Company derived the balance sheet data at December 31, 2014. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Innmune Limited, Coronado SO, Cyprium Inc., Altamira Bio Inc., JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang and Helocyte. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Reclassifications	Reclassifications The Company reclassified debt issuance costs from other assets to notes payable, long-term, net on the unaudited condensed consolidated balance sheets for all periods presented pursuant to the early adoption of Accounting Standards Update ("ASU") No. 2015-03 - Simplifying the Presentation of Debt Issuance Costs
Restricted Cash	Restricted Cash The Company records cash held in trust or pledged to secure certain debt obligations as restricted cash. As of June 30, 2015, the Company has $ 14.6 14.0 0.6
Fair Value Measurement	Fair Value Measurement The Company follows accounting guidance on fair value measurements for financial assets and liabilities measured at fair value on a recurring basis. Under the accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories: Level 1 : Quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Certain of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. The carrying value of the amount owed to Ovamed upon the acquisition of certain manufacturing rights in December 2012 under the amendment to the sublicense agreement with Ovamed included in current liabilities in the June 30, 2015 Unaudited Condensed Consolidated Balance Sheet and both current liabilities and long-term liabilities in the December 31, 2014 Consolidated Balance Sheet, has been recorded at its net present value, which approximates its fair value (see Note 11).
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value, determined based on discounted cash flows. During the three and six month period ended June 30, 2014, in relation to the abandonment of its lease in Woburn, MA, the Company recorded an impairment loss of $ 0.4
Investments at Fair Value	Investments at Fair Value The Company elected the fair value option for its investment in a third-party company developing a laser device to treat migraine headaches, and its investment in CB Pharma Acquisitions Corp (“CB Pharma”). As of June 30, 2015 the fair value of these investments approximate $ 5.6 While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The decision to elect the fair value option, which is irrevocable once elected, is determined on an instrument by instrument basis and applied to an entire instrument. The net gains or losses, if any, on an investment for which the fair value option has been elected, are recognized as a change in fair value of investments, in the Unaudited Condensed Consolidated Statements of Operations.
Revenue Recognition	Revenue Recognition The Company recognizes revenue for the performance of services or the shipment of products when each of the following four criteria is met: (i) persuasive evidence of an arrangement exists; (ii) products are delivered or as services are rendered; (iii) the sales price is fixed or determinable; and (iv) collectability is reasonably assured. The Company follows ASC 605-25, Revenue Recognition Multiple-Element Arrangements Collaborative Arrangements ASC 605-25 provides guidance relating to the separability of deliverables included in an arrangement into different units of accounting and the allocation of arrangement consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. Management then estimates the selling price for each unit of accounting and allocates the arrangement consideration to each unit utilizing the relative selling price method. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the Unaudited Condensed Consolidated Balance Sheets and recognized as revenue in the Unaudited Condensed Consolidated Statements of Operations when the related revenue recognition criteria are met.
Intangible Asset License	Intangible Asset License The Company records the costs of acquired product license rights as intangible asset licenses in the Condensed Consolidated Balance Sheets. Upon commencement of product sales, license rights will be amortized over the expected life of the product into product expense in the Unaudited Condensed Consolidated Statements of Operations. As of June 30, 2015, product sales of the Company’s intangible asset license had not yet commenced (see Note 6).
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50
Non-Controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests (see Note 5).
Comprehensive Loss	Comprehensive Loss The Company’s comprehensive loss is equal to its net loss for all periods presented.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs In the first quarter of 2015, the Company adopted ASU No. 2014-08, Reporting Discontinued operations and Disclosures of Disposals of Components of an Entity In January 2015, the FASB issued ASU 2015-01, which eliminates from GAAP the concept of extraordinary items. If an event or transaction meets the criteria for extraordinary classification, it is segregated from the results of ordinary operations and is shown as a separate item in the income statement, net of tax. ASU 2015-01 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company is currently assessing the adoption and impact of this ASU, however, the Company does not anticipate that adoption of this ASU will impact consolidated financial position and results of operations In May 2014, the FASB issued Accounting Standard Update No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2015
Marketable Securities [Abstract]
Marketable Securities	Marketable securities, classified as trading, consist of the following: As of June 30, 2015 ($ in thousands) Cost Unrealized Gain/(Loss) Fair Value U.S. treasury bill $ 19,998 $ 2 $ 20,000 As of December 31, 2014 ($ in thousands) Cost Unrealized Gain/(Loss) Fair Value U.S. treasury bill $ 19,998 $ - $ 19,998 Mutual fund 4 - 4 $ 20,002 $ - $ 20,002

Licenses Acquired (Tables)

Licenses Acquired (Tables)	6 Months Ended
	Jun. 30, 2015
Research and Development [Abstract]
Research and Development Arrangement, Contract to Perform for Others	For the Six Months ($ in thousands) Ended June 30, 2015 Fortress: EGFR inhibitors $ 1,000 IV Tramadol (1) 3,000 Fortress Companies: Mustang 2,147 Checkpoint 1,033 Coronado SO 1,607 Helocyte 200 Total $ 8,987 (1) The Company intends to transfer this license to Avenue.

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	6 Months Ended
	Jun. 30, 2015
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities are as follows: ($ in thousands) As of June 30, 2015 Avenue Coronado SO Mustang Checkpoint Total NCI equity share 2 23 15 9 49 Net loss attributed to non-controlling interest (34) (230) (267) (191) (722) Non-controlling in consolidated entities $ (32) $ (207) $ (252) $ (182) $ (673)
Components Of Non-Controlling Interests In Loss Of Consolidated Entities	($ in thousands) For the six months ended June 30, 2015 Avenue Coronado SO Mustang Checkpoint Total Non-controlling interests in loss of consolidated entities $ (34) $ (230) $ (267) $ (191) $ (722) Non-controlling ownership (See Note 4) 11.5 % 13.0 % 10.0 % 20.0 %

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Calculation of Basic and Diluted Net Loss Per Share	A calculation of basic and diluted net loss per common share follows: For the three months ended June 30, For the six months ended June 30, ($ in thousands except share and per share amounts) 2015 2014 2015 2014 Net loss (6,175) (4,711) (18,231) (12,081) Weighted average common shares outstanding—basic and diluted 39,119,606 36,005,294 38,848,660 35,953,234 Basic and diluted net loss per common share $ (0.16) $ (0.13) $ (0.47) $ (0.34)
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive: For the three months ended June 30, For the six months ended June 30, 2015 2014 2015 2014 Warrants to purchase Common Stock 685,061 692,916 685,061 702,353 Options to purchase Common Stock 2,071,032 2,187,076 2,114,126 2,384,348 Unvested Restricted Stock 6,912,530 6,308,368 6,749,641 5,662,528 Unvested Restricted Stock Units 11,000 - 6,884 - Total 9,679,623 9,188,360 9,555,712 8,749,229

Debt and Interest (Tables)

Debt and Interest (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	Long-term debt consists of the following as of June 30, 2015 and December 31, 2014: ($ in Thousands) June 30, 2015 December 31, 2014 Interest Rate Maturity IDB Note $ 14,009 $ 14,009 2.25 % Feb - 2017 NSC Note 10,000 - 8.00 % Mar - 2018 Total notes payable, long term 24,009 14,009 Discount of notes payable 777 - Total notes payable, long term, net $ 23,232 $ 14,009
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all of debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: For the three months ended June 30, For the six months ended June 30, ($ in Thousands) 2015 2014 2015 2014 IDB Note Interest $ 82 $ 80 $ 153 $ 121 Amortization of fees 1 1 2 2 Total IDB Note 83 81 155 123 NSC Debt Interest 208 - 279 - Amortization of fees 61 - 82 - Total NSC Debt 269 - 361 - Ovamed Manufacturing Agreement Interest - 38 167 75 Total Ovamed - 38 167 75 Hercules Debt Interest (1) - - - 845 Amortization of fees - - - 42 Total Hercules Debt - - - 887 Total Interest Expense $ 352 $ 119 $ 683 $ 1,085 (1) Interest expense related to the Hercules Note was $ 0.8 0.4

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property Plant And Equipment [Abstract]
Components of Property and Equipment	Property and equipment consisted of the following: ($ in thousands) Useful Life (Years) As of June 30, 2015 As of December 31, 2014 Computer equipment 3 $ 13 $ 13 Furniture & fixtures 5 69 69 Leasehold improvements 5 12 12 Construction in progress N/A 49 - Total property and equipment 143 94 Less: Accumulated depreciation (53) (42) Property and equipment, net $ 90 $ 52

Accrued Expenses and Other Lo27

Accrued Expenses and Other Long-Term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Components of Accrued Expenses and Other Long-Term Liabilities	Accrued expenses and other long-term liabilities consisted of the following: June 30, 2015 December 31, 2014 Accrued expenses: Professional fees $ 359 $ 837 Salaries, bonuses and related benefits 640 598 Accrued milestone, CNDO SO 500 - Accrued severance 6 38 Ovamed manufacturing rights - short term component 1,500 1,000 Research and development 623 832 Lease impairment 165 165 Other 593 213 Total accrued expenses $ 4,386 $ 3,683 Other long-term liabilities: Ovamed manufacturing rights – long-term component - 334 Long-term lease abandonment charge 144 268 Deferred rent 120 120 Total other long-term liabilities $ 264 $ 722

Investments at Fair Value (Tabl

Investments at Fair Value (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables classify into the fair value hierarchy financial instruments measured at fair value on a recurring basis in the accompanying Condensed Consolidated Balance Sheets as of June 30, 2015 (unaudited) and December 31, 2014: Fair Value Measurement as of June 30, 2015 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Marketable securities: U.S. treasury bills $ 20,000 $ - $ - $ 20,000 Total marketable securities 20,000 - - 20,000 Long-term investments, at fair value - - 5,567 5,567 Total $ 20,000 $ - $ 5,567 $ 25,567 Fair Value Measurement as of December 31, 2014 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Marketable securities: U.S. treasury bills $ 19,998 $ - $ - $ 19,998 Mutual funds 4 - 4 Total marketable securities 20,002 - - 20,002 Long-term investments, at fair value - - 4,160 4,160 Total $ 20,002 $ - $ 4,160 $ 24,162
Schedule of changes in fair value of financial instruments	The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments, as of June 30, 2015: ($ in thousands) Other CB Pharma Total Balance at December 31, 2014 $ 250 $ 3,910 $ 4,160 Purchases - - - Change in fair value of investment - 1,407 1,407 Balance at June 30, 2015 $ 250 $ 5,317 $ 5,567

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Activity	The following table summarizes the stock-based compensation expense from stock option awards, restricted common stock awards, employee stock purchase programs and warrants granted by Fortress for the three and six months ended June 30, 2015 and 2014: For the three months ended June 30, For the six months ended June 30, ($ in thousands) 2015 2014 2015 2014 Employee awards $ 1,525 $ 1,452 $ 2,988 $ 2,574 Non-employee awards 7 11 14 24 Fortress Companies (1) 35 - 393 - Total stock-based compensation expense $ 1,574 $ 1,463 $ 3,395 $ 2,598 (1) Includes for Avenue $ 22,900 178,500 32,500 12,242 147,000
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies: Weighted average Total weighted remaining Weighted average average intrinsic contractual life ($ in thousands) Number of shares exercise price value (years) Options vested and expected to vest at December 31, 2014 2,164,365 $ 4.69 $ - 7.38 Options granted - - - Options exercised (100,000) 2.15 1.21 Options cancelled - - - Options vested and expected to vest at June 30, 2015 2,064,365 $ 4.82 $ - 7.20 Options vested and exercisable 1,747,698 $ 4.75 $ - 6.79
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress’ restricted stock award and restricted stock unit activity, excluding activity related to Fortress Companies: Weighted average grant date fair Number of shares value Unvested balance at December 31, 2014 8,287,384 $ 2.33 Restricted stock granted 200,000 3.04 Restricted stock vested (783,115) 2.43 Restricted stock units granted 61,000 2.34 Restricted stock units vested (25,000) 2.19 Unvested balance at June 30, 2015 7,740,269 $ 2.34

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Accounting Policies [Line Items]
Percentage of tax benefit likely of being realized		50.00%
Restricted Cash and Cash Equivalents		$ 14.6
Gain (Loss) on Sale of Assets and Asset Impairment Charges	$ 0.4		$ 0.4
CB Pharma Acquisitions Corp [Member]
Accounting Policies [Line Items]
Fair Value, Assets Measured on Recurring Basis, Change in Unrealized Gain (Loss)		5.6
Hercules Note Payble [Member]
Accounting Policies [Line Items]
Restricted Cash and Cash Equivalents		0.6
Debt Instrument, Periodic Payment		$ 14

Marketable Securities (Detail)

Marketable Securities (Detail) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Marketable securities, Cost			$ 20,002
Marketable securities, Unrealized Gain/(Loss)	$ (2)	$ 0	0
Marketable securities, Fair value	20,000		20,002
U.S. treasury bill
Marketable securities, Cost	19,998		19,998
Marketable securities, Unrealized Gain/(Loss)	2		0
Marketable securities, Fair value	$ 20,000		19,998
Mutual fund
Marketable securities, Cost			4
Marketable securities, Unrealized Gain/(Loss)			0
Marketable securities, Fair value			$ 4

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total		$ 1,548	$ 0	$ 8,987	$ 0
EGFR inhibitors [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total				1,000
IV Tramadol [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	[1]			3,000
Mustang Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total				2,147
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total				1,033
Coronado SO Co, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total				1,607
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total				$ 200
[1]	The Company intends to transfer this license to Avenue.

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($)		1 Months Ended		3 Months Ended		6 Months Ended
		Apr. 28, 2015	Apr. 02, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets						$ 1,250,000	$ 0
Research And Development In Process				$ 1,548,000	$ 0	8,987,000	0
Stock Issued During Period, Value, Issued for Services						1,000	4,000
Research And Development Expense				$ 2,411,000	$ 2,377,000	$ 4,066,000	$ 6,865,000
Share Price				$ 9.52		$ 9.52
Scientific Advisory Board [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Issued for Services						1,500,000
Stock Issued During Period, Value, Issued for Services						$ 200,000
Dana Farber Cancer Institute [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital						44.80%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent						30.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						500,000
Share Price				$ 0.065		$ 0.065
Dana Farber Cancer Institute [Member] | Research and Development Expense [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development Expense						$ 32,500
Collaboration Agreement with TGTX [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees						500,000
Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees				$ 0		500,000
Agreement With City Of Hope [Member] | Mustang Bio, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire in Process Research and Development						$ 2,000,000
Restricted Stock Purchase Agreement [Member] | Dana Farber Cancer Institute [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital						44.80%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent						30.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						48 months
Share Price				$ 0.065		$ 0.065
Stock Issued						$ 100,000
Chief Executive Officer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Issued for Services						1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						grant vests 50% in four annual equal tranches of 12.5%, with the remaining 50% vesting upon the achievement of certain performance goals.
EGFR inhibitors [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process						$ 1,000,000
IV Tramadol [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital						44.80%
Research And Development In Process	[1]					$ 3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent						30.00%
Share Price				$ 0.146		$ 0.146
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process						$ 1,033,000
Research And Development Expense				$ 9,000		12,000
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process						200,000
Helocyte Biosciences Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development Expense						200,000
Licensing Agreements [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets		$ 50,000	$ 150,000
Licensing Agreements [Member] | NeuPharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees						$ 1,000,000
Licensing Agreements [Member] | City Of Hope [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital						0.00%
Payments for Fees						$ 2,000,000
Stock Issued During Period, Shares, Other						1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent						0.00%
Research And Development Expense						$ 100,000
Share Price				$ 0.147		$ 0.147
Stock Issued During Period, Value, Other						$ 100,000
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued			500,000
Licensing Agreements [Member] | Dana Farber Cancer Institute [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees						$ 1,000,000
Licensing Agreements [Member] | Dana Farber Cancer Institute [Member] | Research and Development Expense [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Other						500,000
Licensing Agreements [Member] | Coronado SO [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Marketability Percentage Of Invested Capital						44.80%
Payments for Fees						$ 900,000
Stock Issued During Period, Shares, Other						150,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent						30.00%
Research And Development Expense						$ 1,400,000
Share Price				$ 1.19		$ 1.19
Stock Issued During Period, Value, Other						$ 200,000
Licensing Agreements [Member] | Coronado SO [Member] | Scenario, Forecast [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees						500,000
Licensing Agreements [Member] | IV Tramadol [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments to Acquire Intangible Assets						1,000,000
Payments for Fees						2,000,000
Licensing Agreements [Member] | Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Value, Purchase of Assets						500,000
Avenue Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Value, Issued for Services				$ 23,000		$ 23,000
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Issued for Services				1,000,000
Avenue Therapeutics, Inc. [Member] | Consultants [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Issued for Services				150,000		150,000
[1]	The Company intends to transfer this license to Avenue.

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Noncontrolling Interest [Line Items]
NCI equity share			$ 49
Net loss attributed to non-controlling interest	$ (243)	$ 0	(722)	$ 0
Non-controlling in consolidated entities	(673)		(673)		$ 0
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share			2
Net loss attributed to non-controlling interest			(34)
Non-controlling in consolidated entities	(32)		(32)
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share			23
Net loss attributed to non-controlling interest			(230)
Non-controlling in consolidated entities	(207)		(207)
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share			15
Net loss attributed to non-controlling interest			(267)
Non-controlling in consolidated entities	(252)		(252)
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share			9
Net loss attributed to non-controlling interest			(191)
Non-controlling in consolidated entities	$ (182)		$ (182)

Non-Controlling Interests - S35

Non-Controlling Interests - Summary Of Components of Non-Controlling Interests in Loss of Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (243)	$ 0	$ (722)	$ 0
Avenue [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities			$ (34)
Non-controlling ownership (See Note 4)	11.50%		11.50%
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities			$ (230)
Non-controlling ownership (See Note 4)	13.00%		13.00%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities			$ (267)
Non-controlling ownership (See Note 4)	10.00%		10.00%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities			$ (191)
Non-controlling ownership (See Note 4)	20.00%		20.00%

Intangible Asset License - Addi

Intangible Asset License - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets		$ 1,250	$ 0
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets	$ 1,300
License Costs	$ 700

Net Loss Per Common Share - Cal

Net Loss Per Common Share - Calculation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator
Net loss	$ (6,175)	$ (4,711)	$ (18,231)	$ (12,081)
Denominator
Weighted average common shares outstanding—basic and diluted	39,119,606	36,005,294	38,848,660	35,953,234
Basic and diluted net loss per common share	$ (0.16)	$ (0.13)	$ (0.47)	$ (0.34)

Net Loss Per Common Share - Com

Net Loss Per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	9,679,623	9,188,360	9,555,712	8,749,229
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	685,061	692,916	685,061	702,353
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	2,071,032	2,187,076	2,114,126	2,384,348
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	6,912,530	6,308,368	6,749,641	5,662,528
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	11,000	0	6,884	0

Net Loss Per Common Share - Add

Net Loss Per Common Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	9,679,623	9,188,360	9,555,712	8,749,229
Restricted Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount			7,704,269

Debt and Interest (Detail)

Debt and Interest (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Debt [Line Items]
Total notes payable, long term	$ 24,009	$ 14,009
Discount of notes payable	777	6
Total notes payable, long term, net	23,232	14,003
IDB Note [Member]
Debt [Line Items]
Total notes payable, long term	$ 14,009	14,009
Interest Rate	2.25%
Maturity Date	Feb - 2017
NSC Note [Member]
Debt [Line Items]
Total notes payable, long term	$ 10,000	$ 0
Interest Rate	8.00%
Maturity Date	Mar - 2018

Debt and Interest (Details 1)

Debt and Interest (Details 1) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Debt [Line Items]
Interest				$ 800
Interest expense related to the Hercules loan		$ 352	$ 119	683	$ 1,085
IDB Note [Member]
Debt [Line Items]
Interest		82	80	153	121
Amortization of fees		1	1	2	2
Interest and Debt Expense, Total		83	81	155	123
NSC Debt [Member]
Debt [Line Items]
Interest		208	0	279	0
Amortization of fees		61	0	82	0
Interest and Debt Expense, Total		269	0	361	0
Ovamed Manufacturing Agreement [Member]
Debt [Line Items]
Interest		0	38	167	75
Interest and Debt Expense, Total		0	38	167	75
Hercules Debt [Member]
Debt [Line Items]
Interest	[1]	0	0	0	845
Amortization of fees		0	0	0	42
Interest and Debt Expense, Total		$ 0	$ 0	$ 0	$ 887
[1]	Interest expense related to the Hercules Note was $0.8 million, including $0.4 million related to accretion of the debt discount.

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015
Debt [Line Items]
Interest Expense, Debt			$ 800
Accretion of Discount			$ 400
Debt Instrument, Interest Rate, Effective Percentage	9.00%		9.00%
IDB Promissory Note Payable [Member]
Debt [Line Items]
Notes Payable	$ 14,000		$ 14,000
NSC Notes Payable [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%		8.00%
Debt Instrument, Fee Amount	$ 900		$ 900
Interest Expense, Debt	$ 208	$ 0	$ 279	$ 0
Notes Payable					$ 10,000
NSC [Member]
Debt [Line Items]
Debt Instrument, Term			10 years

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 143	$ 94
Less: Accumulated depreciation	(53)	(42)
Property and equipment, net	90	52
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 13	13
Useful Life (Years)	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 69	69
Useful Life (Years)	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 12	12
Useful Life (Years)	5 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 49	$ 0

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Property Plant And Equipment [Line Items]
Depreciation	$ 5,000	$ 6,000	$ 11,000	$ 11,000

Accrued Expenses and Other Lo45

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Accrued expenses:
Professional fees	$ 359	$ 837
Salaries, bonuses and related benefits	640	598
Accrued milestone, CNDO SO	500	0
Accrued severance	6	38
Ovamed manufacturing rights - short term component	1,500	1,000
Research and development	623	832
Lease impairment	165	165
Other	593	213
Total accrued expenses	4,386	3,683
Other long-term liabilities:
Ovamed manufacturing rights - long-term component	0	334
Long-term lease abandonment charge	144	268
Deferred rent	120	120
Total other long-term liabilities	$ 264	$ 722

Accrued Expenses and Other Lo46

Accrued Expenses and Other Long-Term Liabilities - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 12, 2014	Dec. 31, 2012
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]
Other Accrued Liabilities, Current	$ 593,000		$ 593,000				$ 213,000
Asset Retirement Obligation, Accretion Expense	38,000	$ 38,000	167,000	$ 75,000
Capital Leases, Future Minimum Payments Receivable, Next Twelve Months								$ 500,000
Subsequent Event [Member]
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]
Capital Leases, Future Minimum Payments, Receivable in Two Years						$ 500,000
Capital Leases, Future Minimum Payments, Receivable in Three Years					$ 500,000
Ovamed Manufacturing Rights [Member]
Schedule Accrued Expenses And Other Long-Term Liabilities [Line Items]
Other Liabilities									$ 1,500,000
Other Accrued Liabilities, Current	$ 1,500,000		$ 1,500,000

Fair Value Hierarchy Financial

Fair Value Hierarchy Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	$ 20,000	$ 20,002
Long-Term Investments, at fair value	5,567	4,160
Total	25,567	24,162
U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	20,000	19,998
Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities		4
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	20,000	20,002
Long-Term Investments, at fair value	0	0
Total	20,000	20,002
Fair Value, Inputs, Level 1 [Member] | U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	20,000	19,998
Fair Value, Inputs, Level 1 [Member] | Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities		4
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	0	0
Long-Term Investments, at fair value	0	0
Total	0	0
Fair Value, Inputs, Level 2 [Member] | U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	0	0
Fair Value, Inputs, Level 2 [Member] | Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	0	0
Long-Term Investments, at fair value	5,567	4,160
Total	5,567	4,160
Fair Value, Inputs, Level 3 [Member] | U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	$ 0	$ 0
Fair Value, Inputs, Level 3 [Member] | Mutual Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities

Changes in Fair Value of Financ

Changes in Fair Value of Financial Instruments (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	$ 4,160
Purchases	0
Change in fair value of investment	1,407
Balance at June 30, 2015	5,567
CB Pharma Acquisitions Corp [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	3,910
Purchases	0
Change in fair value of investment	1,407
Balance at June 30, 2015	5,317
Other Long-term Investments [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at December 31, 2014	250
Purchases	0
Change in fair value of investment	0
Balance at June 30, 2015	$ 250

Investments at Fair Value - Add

Investments at Fair Value - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments	$ 250,000	$ 250,000
Trading Securities	$ 20,000,000	20,002,000
Fair Value Assumptions, Weighted Average Volatility Rate	25.40%
Share Price	$ 9.52
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease)	$ 1,400,000
Investment Owned, at Fair Value	5,300,000
Working Capital	500,000
Working Capital Committed	$ 100,000
Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price	$ 0.86
Non Redeemable warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price	$ 0.87
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	1.63%
Fair Value Assumptions, Expected Volatility Rate	25.40%
Fair Value Assumptions, Exercise Price	$ 11.50
US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading Securities	$ 20,000,000	$ 20,000,000
Common Stock Subject to Mandatory Redemption [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net Assets	$ 42,900,000
Private Units [Member] | Ghaidarov Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price	$ 9.52

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 1,574	$ 1,463	$ 3,395	$ 2,598
Fortress Companies [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	[1]	35	0	393	0
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		1,525	1,452	2,988	2,574
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 7	$ 11	$ 14	$ 24
[1]	Includes for Avenue $22,900 for compensation expense on stock grants, Coronado SO $178,500 for stock a grant in connection with a license acquired, Checkpoint $32,500 for a stock grant in connection with a license acquired and $12,242 for compensation expense and Mustang $147,000 for a stock grant in connection with the license acquired.

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares,Outstanding at December 31, 2014	2,164,365
Number of Shares, Options granted	0
Number of Shares, Options exercised	(100,000)
Number of Shares,Options cancelled	0
Number of Shares, Outstanding at March 31, 2015	2,064,365	2,164,365
Number of Shares, Options vested and exercisable	1,747,698
Weighted Average Exercise Price,Outstanding at December 31, 2014	$ 4.69
Weighted Average Exercise Price, Options granted	0
Weighted Average Exercise Price, Options exercised	2.15
Weighted Average Exercise Price,Options cancelled	0
Weighted Average Exercise Price, Outstanding at March 31, 2015	4.82	$ 4.69
Weighted Average Exercise Price, Options vested and expected to vest	$ 4.75
Total Weighted Average Intrinsic Value,Outstanding at December 31, 2014	$ 0
Total Weighted Average Intrinsic Value,Options exercised	1,210
Total Weighted Average Intrinsic Value, Options vested and exercisable	$ 0
Weighted Average Remaining Contractual Life, Outstanding	7 years 2 months 12 days	7 years 4 months 17 days
Weighted Average Remaining Contractual Life, Options vested and exercisable	6 years 9 months 14 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail) - 6 months ended Jun. 30, 2015 - Restricted Stock [Member] - $ / shares shares in Thousands	Total
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested balance at December 31, 2014	8,287,384
Restricted stock granted	200,000
Restricted stock vested	(783,115)
Restricted stock units granted	61,000
Restricted stock units vested	(25,000)
Unvested balance at June 30, 2015	7,740,269
Unvested balance at December 31, 2014	$ 2.33
Restricted stock granted (Fair Value)	3.04
Restricted stock vested (Fair Value)	2.43
Restricted stock units granted (Fair Value)	2.34
Restricted stock units vested (Fair Value)	2.19
Unvested balance at June 30, 2015	$ 2.34

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to all unvested stock option	$ 700,000			$ 700,000
Employee Stock Purchase Plan to eligible employees, Number of shares purchased by employees	77,875			77,875
Employee Stock Purchase Plan to eligible employees, Number of shares available for future sales	122,125			122,125
Employee Stock Purchase Plan to eligible employees, compensation expense recognized	$ 8,465		$ 7,128	$ 14,848	$ 15,746
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	14,300,000			$ 14,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				4 months 24 days
Stock Issued During Period, Value, Issued for Services				$ 1,000	4,000
Employee Benefits And Share Based Compensation	$ 1,574,000		1,463,000	$ 3,395,000	2,598,000
Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services				1,000,000
Avenue Therapeutics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Market Value Percentage of Invested Capital	44.80%
Shares Issued, Price Per Share	$ 0.146			$ 0.146
Stock Issued During Period, Value, Issued for Services	$ 23,000			$ 23,000
Employee Benefits And Share Based Compensation				$ 22,900
Avenue Therapeutics, Inc. [Member] | Consultants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services	150,000			150,000
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services	1,000,000
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	12.50%
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Three [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Coronado SO Co. [Member] | Acquisition Of License [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Benefits And Share Based Compensation				$ 178,500
Mustang Bio, Inc [Member] | Acquisition Of License [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Benefits And Share Based Compensation				147,000
Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 9,200			12,200
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total		$ 1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		48 months
Weighted Market Value Percentage of Invested Capital		44.80%
Weighted Average Cost Percentage of Capital		30.00%
Shares Issued, Price Per Share		$ 0.065
Employee Benefits And Share Based Compensation				12,242
Checkpoint Therapeutics, Inc [Member] | Acquisition Of License [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Benefits And Share Based Compensation				$ 32,500
Warrant [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Outstanding	685,061			685,061
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 6.65
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 300,000		300,000	$ 500,000	600,000
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 1,300,000		$ 1,200,000	$ 2,500,000	$ 2,000,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				2 years 6 months
Deferred Compensation Arrangement with Individual, Shares Issued				250,000

Related Party Note - Additional

Related Party Note - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Related Party Transaction [Line Items]
Costs and Expenses, Related Party	$ 44,400	$ 38,400	$ 87,700	$ 38,400
Cb Pharma Acquisition Corp [Member]
Related Party Transaction [Line Items]
Accounts Receivable, Related Parties	$ 100,000		100,000		$ 0
Collaboration Agreement with TGTX [Member]
Related Party Transaction [Line Items]
Payments for Fees			$ 500,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) € in Millions	Jul. 15, 2015	Jul. 16, 2015USD ($)	Jul. 15, 2015shares	Apr. 28, 2015USD ($)	Apr. 02, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)	Aug. 03, 2015USD ($)	Aug. 03, 2015EUR (€)
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets								$ 1,250,000	$ 0
Research And Development Expense						$ 2,411,000	$ 2,377,000	$ 4,066,000	$ 6,865,000
Restricted Stock [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares								200,000,000
Dov Klein [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number | shares			50,000
Licensing Agreements [Member]
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets				$ 50,000	$ 150,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross		$ 50,000
Due to Related Parties										$ 2,700,000	€ 2.5
Subsequent Event [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	The restricted shares vest 10% immediately and an additional 10% per year over four years commencing the later of trading availability, under Fortress Insider Trading Policy, or July 15, 2015. The remaining 50% vests in accordance with the achievement of performance goals.
Subsequent Event [Member] | Director [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number | shares			133,000
Subsequent Event [Member] | Dov Klein [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
Subsequent Event [Member] | Vice President [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares			1,000,000
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Surrendered In Period | shares			200,000
Subsequent Event [Member] | Licensing Agreements [Member]
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets		1,300,000
Subsequent Event [Member] | Licensing Agreements [Member] | New Zealand Pharmaceuticals Ltd [Member]
Subsequent Event [Line Items]
Payments to Acquire Intangible Assets		700,000
Research And Development Expense		$ 600,000